Nana Andre Wendindonde, Yang Pei-Ming, Lin Hung-Yun
Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan E-mail :
Asian Pac J Cancer Prev. 2015;16(16):6813-23. doi: 10.7314/apjcp.2015.16.16.6813.
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive of human brain tumors and has a stunning progression with a mean survival of one year from the date of diagnosis. High cell proliferation, angiogenesis and/or necrosis are histopathological features of this cancer, which has no efficient curative therapy. This aggressiveness is associated with particular heterogeneity of the tumor featuring multiple genetic and epigenetic alterations, but also with implications of aberrant signaling driven by growth factors. The transforming growth factor β (TGFβ) superfamily is a large group of structurally related proteins including TGFβ subfamily members Nodal, Activin, Lefty, bone morphogenetic proteins (BMPs) and growth and differentiation factor (GDF). It is involved in important biological functions including morphogenesis, embryonic development, adult stem cell differentiation, immune regulation, wound healing and inflammation. This superfamily is also considered to impact on cancer biology including that of GBM, with various effects depending on the member. The TGFβ subfamily, in particular, is overexpressed in some GBM types which exhibit aggressive phenotypes. This subfamily impairs anti-cancer immune responses in several ways, including immune cells inhibition and major histocompatibility (MHC) class I and II abolishment. It promotes GBM angiogenesis by inducing angiogenic factors such as vascular endothelial growth factor (VEGF), plasminogen activator inhibitor (PAI-I) and insulin- like growth factor-binding protein 7 (IGFBP7), contributes to GBM progression by inducing metalloproteinases (MMPs), "pro-neoplastic" integrins (αvβ3, α5β1) and GBM initiating cells (GICs) as well as inducing a GBM mesenchymal phenotype. Equally, Nodal promotes GICs, induces cancer metabolic switch and supports GBM cell proliferation, but is negatively regulated by Lefty. Activin promotes GBM cell proliferation while GDF yields immune-escape function. On the other hand, BMPs target GICS and induce differentiation and sensitivity to chemotherapy. This multifaceted involvement of this superfamily in GBM necessitates different strategies in anti-cancer therapy. While suppressing the TGFβ subfamily yields advantageous results, enhancing BMPs production is also beneficial.
胶质母细胞瘤,也称为多形性胶质母细胞瘤(GBM),是最具侵袭性的人类脑肿瘤,其进展惊人,从诊断之日起平均生存期为一年。高细胞增殖、血管生成和/或坏死是这种癌症的组织病理学特征,目前尚无有效的治愈性疗法。这种侵袭性与肿瘤的特殊异质性有关,其特征是存在多种基因和表观遗传改变,也与生长因子驱动的异常信号传导有关。转化生长因子β(TGFβ)超家族是一大类结构相关的蛋白质,包括TGFβ亚家族成员Nodal、激活素、Lefty、骨形态发生蛋白(BMP)和生长分化因子(GDF)。它参与重要的生物学功能,包括形态发生、胚胎发育、成体干细胞分化、免疫调节、伤口愈合和炎症。这个超家族也被认为会影响癌症生物学,包括GBM的生物学,其影响因成员而异。特别是,TGFβ亚家族在一些表现出侵袭性表型的GBM类型中过度表达。该亚家族通过多种方式损害抗癌免疫反应,包括抑制免疫细胞以及消除主要组织相容性(MHC)I类和II类分子。它通过诱导血管内皮生长因子(VEGF)、纤溶酶原激活物抑制剂(PAI-I)和胰岛素样生长因子结合蛋白7(IGFBP7)等血管生成因子促进GBM血管生成,通过诱导金属蛋白酶(MMP)、“促肿瘤”整合素(αvβ3、α5β1)和GBM起始细胞(GIC)以及诱导GBM间充质表型促进GBM进展。同样,Nodal促进GIC,诱导癌症代谢转换并支持GBM细胞增殖,但受Lefty负调控。激活素促进GBM细胞增殖,而GDF产生免疫逃逸功能。另一方面,BMP靶向GIC并诱导分化和对化疗的敏感性。这个超家族在GBM中的多方面参与使得抗癌治疗需要采取不同的策略。虽然抑制TGFβ亚家族会产生有利结果,但增强BMP的产生也有益处。